Active Biotech AB Interim report January - March 2015

April 23, 2015 08:30 (CEST)

Laquinimod

  • The pivotal CONCERTO clinical study is continuing according to plan and results are expected in 2016
  • Teva is holding a number of presentations of laquinimod at the AAN Annual Meeting on April 18-25 

Tasquinimod     

  • Results from the Phase III study 10TASQ10 showed that treatment with tasquinimod reduced the risk of radiographic cancer progression or death compared to placebo (rPFS, HR=0.69, CI 95%: 0.60 - 0.80) in patients with metastatic castration resistant prostate cancer (mCRPC) who have not received chemotherapy, but did not extend overall survival (OS, HR=1.09, CI 95%: 0.94 - 1.28)
  • Further development of tasquinimod for the treatment of prostate cancer has been discontinued. The collaboration agreement with Ipsen will accordingly cease.

ISI          

  • The project is currently focusing on building up a patent portfolio

Financial summary

MSEK   Jan. - Mar.   Jan. - Dec.
  2015 2014   2014  
Net sales 2.9 2.1   10.4  
           
Operating loss -57.4 -59.2   -228.5  
Loss for the period -58.0 -60.2   -231.5  
Loss per share (SEK) -0.64 -0.80   -3.02  
Cash and cash equivalents  270.5 298.5   328.5  

 For further information, please contact:                    

  Tomas Leanderson, President and CEO
  Tel: +46 (0)46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44
  The report is also available at www.activebiotech.com
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
   
Active Biotech AB Interim report January - March 2015